​

Funding Round

Series B - ArsenalBio

Series B - ArsenalBio

Investment Firm

Overview

ArsenalBio is a programmable cell therapy company that offers advanced CAR T-cell therapies for solid tumors.

Announced Date

Sep 06, 2022

Funding Type

Series B

Highlights

Location

United States, North America

Social

Investor Lead

N/A

Participant Investors

8

Investor Name
Participant InvestorBristol-Myers Squibb
Participant InvestorKleiner Perkins
Participant InvestorUniversity of California, San Francisco
Participant InvestorEmerson Collective
Participant InvestorHitachi Ventures

Round Details and Background

ArsenalBio raised $220806682 on 2022-09-06 in Series B

ArsenalBio is a programmable cell therapy company that offers advanced CAR T-cell therapies for solid tumors.

Company Funding History

2

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
Oct 17, 2019
Series A - ArsenalBio
7-85.0M
Sep 06, 2022
Series B - ArsenalBio
14-220.8M

Recent Activity

There is no recent news or activity for this profile.